Tourmaline Bio, Inc.

Tourmaline Bio, Inc.

TRML·NASDAQ

$47.98

+0.0000%
HealthcareBiotechnology

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops medicines and therapies for the Atherosclerotic cardiovascular disease (ASCVD) and Thyroid Eye Disease (TED). The company was incorporated in 2021 and is based in New York, New York.

At a Glance

Live Snapshot
Market Cap$1.23B
EPS-2.8900
P/E Ratio-7.02
Earnings Date04/30/2026

trml

Other Current Assets

Last Annual Value

10.54M

3-Year CAGR

154%

5-Year CAGR

206%

10-Year CAGR

75%

Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Competitors Analysis of Other Current Assets

TRML · NASDAQ
CompanyOther Current Assets
CAGR 3Y
CAGR 5Y
CAGR 10Y
10.54M
21.2%75.1%N/A 
6.60M
-23.8%13.9%N/A
5.04M
115.5%6.0%61.8%
12.26M
6.8%N/AN/A
6.98M
16.5%N/AN/A
PGEN logo
Precigen, Inc.
NASDAQ:PGEN
3.43M
-7.4%-38.5%-6.9%
23.76M
92.8%68.2%N/A
63.26M
901.4%198.9%58.9%
5.21M
9.3%N/AN/A
Tourmaline Bio, Inc.

Tourmaline Bio, Inc. Fair Value Envelope

TRML · NASDAQ

Our analysis suggests that TRML has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $47.98, this represents a potential HIDDEN relative to our calculated worth for Tourmaline Bio, Inc..

Intrinsic Value
Current Price: $47.98